Filing Flows › Aytu Biopharma (AYTU) › Q3 FY26 › vs Q2 FY26
Aytu Biopharma (AYTU) Q3 FY26 vs Q2 FY26 (quarter over quarter)
Aytu Biopharma's revenue fell $2.8M (-18%) from $15.2M in Q2 FY26 to $12.4M in Q3 FY26.
Aytu Biopharma, Q3 FY26: revenue $12.4M (-33% year over year), operating margin -32.7%, net loss $5.6M, operating cash flow −$4.2M. The chart draws each line against Q2 FY26, the increases inside each band.
Every line
| Line | Q3 FY26 | Q2 FY26 | Change | % |
|---|---|---|---|---|
| Revenue | $12.4M | $15.2M | −$2.8M | -18% |
| Net loss | $5.6M | $10.6M | −$5.0M | -47% |
| Costs & expenses | $18.0M | $25.7M | −$7.7M | -30% |
| Operating costs | $16.5M | $17.1M | −$660K | -4% |
| Interest & other, net | $1.5M | $8.6M | −$7.1M | -82% |
| Income tax | $10K | $0 | $10K | — |
| Cost of revenue | $4.8M | $5.5M | −$729K | -13% |
| Sales & marketing | $5.9M | $6.0M | −$69K | -1% |
| General & admin | $5.0M | $5.1M | −$97K | -2% |
| Other operating costs | $761K | $526K | $235K | +45% |
| Operating cash sources | $5.6M | $10.6M | −$5.0M | -47% |
| Depreciation & amortization | $1.1M | $885K | $236K | +27% |
| Share-based compensation | $148K | $283K | −$135K | -48% |
| Working capital & other | $167K | $13.1M | −$12.9M | -99% |
| Cash used in operations | $4.2M | −$3.7M | $7.9M | — |
| Net loss absorbed | $5.6M | $10.6M | −$5.0M | -47% |
Questions
How much did Aytu Biopharma's revenue grow quarter over quarter in Q3 FY26?
Aytu Biopharma's revenue fell $2.8M (-18%) from $15.2M in Q2 FY26 to $12.4M in Q3 FY26.